Evidence map›Paper›PMID 40259553›Full record

ArticleRenal failure2025

Safflower injection against obesity-induced mice podocyte injury by improving insulin resistance through increasing renal INSR and eNOS expression.

Zhaodi Han, Xinyu Wang, Jing Liu, Rui Wang, Wenyan Zhao, Hui Liao

Abstract read
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Biomolecules · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhaodi HanDrug Clinical Trial Institution of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China.ORCID 0000-0001-7839-4896
Xinyu WangDrug Clinical Trial Institution of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China.ORCID 0009-0004-2339-3799
Jing LiuDrug Clinical Trial Institution of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China.ORCID 0000-0001-5101-6510
Rui WangDrug Clinical Trial Institution of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China.ORCID 0009-0004-9729-1496
Wenyan ZhaoDrug Clinical Trial Institution of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China.ORCID 0009-0004-9462-7855
Hui LiaoDrug Clinical Trial Institution of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China.ORCID 0000-0001-6325-062X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPodocyte injury is a common pathologic mechanism in obesity-related glomerulopathy (ORG). Safflower injection (SFI), scientifically extracted and refined from safflower, is used to treat diabetic kidney disease according to clinical guideline. Our previous study confirmed that the main active compounds of SFI ameliorated high glucose-induced podocyte injury. It is uncertain whether SFI has an effect on ORG-related podocyte injury.

objectivesThis study aimed to explore the pharmacological effects and related mechanisms of SFI on podocyte injury of ORG mice.

methodsFirst, by combining ultra-high performance liquid chromatography tandem mass spectrometry analysis with online databases, the pathway enrichment, target-pathway analysis, and human protein-protein interaction network were conducted to discover the possible crucial mechanism of SFI against ORG. Then, ORG mice model was established by high-fat diet and biochemical assays, histopathology and western blot were used to explore the effects of SFI on obesity and podocyte injury. Finally, system pharmacology-based findings were evaluated in ORG mice.

resultsThe results of system pharmacology suggested that SFI could alleviate ORG through insulin resistance (IR)-related pathway by regulating insulin receptor (INSR) and endothelial nitric oxide synthase (eNOS) expressions. The

conclusionsOur findings imply that by up-regulating the expression of renal INSR and eNOS, thereby inhibiting IR, SFI may be a promising candidate for the treatment of ORG.

Indexed as

Carthamus tinctoriusInsulin ResistanceNitric Oxide Synthase Type IIIObesityPodocytesReceptor, InsulinAnimalsDiabetic NephropathiesDiet, High-FatDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLNitric Oxide Synthase Type IIINos3 protein, mouseReceptor, InsulineNOSinsulin resistanceobesity-related glomerulopathypodocyte injurySafflower injection

Identifiers

PMID40259553
PMCPMC12016271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.